The approval will allow in the elimination of a follow-up X-ray when the Celerity system is used to assist in positioning Peripherally Inserted Central Catheters (PICCs) in adults.

The system is said to work by using the patient’s cardiac electrical activity to provide real time catheter tip location, noted AngioDynamics.

AngioDynamics president and CEO Joseph DeVivo said: "This new indication will provide more efficient use for patients and clinicians, and unlock the potential of BioFlo PICCs for customers who rely on a tip location device exclusively."

AngioDynamics vascular access business senior vice-president Chuck Greiner said: "The cost savings associated with using the Celerity system to aid in PICC placements has created a strong demand from our clients."

Earlier, the company received FDA approval for Celerity tip location system, as an adjunct to help in positioning peripherally inserted central catheters in adults by providing real time catheter tip location utilizing the patient’s cardiac electrical activity.

AngioDynamics develops and markets medical devices for vascular access, surgery, peripheral vascular disease and oncology.